Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

The 10-year disease-free and overall survival rate is presented from a trial of adjuvant therapy (chemo-, or immunotherapy) for Dukes’ B and C colon cancer conducted by the National Surgical Adjuvant Breast and Bowel cooperative group. The disease-free and overall survival advantage for the chemotherapy arm, apparent at 5 years, was no longer evident by 10 years.

The Long Look: 10-Year Follow-Up of Adjuvant Colon Trial NSABP C-01